Showing 5261-5270 of 7761 results for "".
- Survey Results Address Role of UPF Clothing; Top Sunscreenshttps://practicaldermatology.com/news/20120416-survey_results_address_role_of_upf_clothing_top_sunscreens__results_of_a_survey_conducted_at_the_70th_annual_aad_meeting_reveal_that_an_overwhelming_m/2459823/Results of a survey conducted at the 70th Annual AAD Meeting reveal that an overwhelming majority of dermatologists categorize UPF clothing as a first line of defense in sun protection, followed by sunscreen. Respondents also named their top sunscreen choices. The survey, organized by
- Vichy Partners With timeRAZOR for Free iPhone, Android Apphttps://practicaldermatology.com/news/20120404-vichy_partners_with_timerazor_for_free_iphone_android_app/2459828/With the new timeRAZOR app, Vichy and timeRAZOR help keep users in the know on events occurring close to where they work, live, or plan to be. timeRAZOR pairs technologic components like geolocation with its own Massive Event Selection Engine, i
- Olympic Swimmer Dara Torres Named Brand Ambassador for AmLactinhttps://practicaldermatology.com/news/20120329-olympic_swimmer_dara_torres_named_brand_ambassador_for_amlactin/2459830/AmLactin Alpha-Hydroxy Skin Care is kicking off the new “Ultra Skin Performance” campaign (Upsher-Smith Laboratories, Inc.) and has named 12-time Olympic medalist Dara Torres its first-ever brand ambassador . The “Ultra Skin Performance” campaign educates women of all ages about the internal and ext
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Phase 3 Trials launching for adalimumab for hidradenitis suppurativahttps://practicaldermatology.com/news/20120315-phase_3_trials_launching_for_adalimumab_for_hidradenitis_suppurativa/2459842/Two Phase 3 clinical trials are underway to evaluate the safety and efficacy of Abbott's Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS). The
- FDA's 45-day TV ad reviewhttps://practicaldermatology.com/news/20120313-fdas_45-day_tv_ad_review_shot_clock_in_guidance/2459846/TV ads for most prescription drugs must be submitted to FDA for pre-review 45 days before the manufacturer intends to air them, according to an FDA draft guidance in tomorrow's Federal Register. The guidance isn't a bolt from the blue but rather a case of the agency catching up on old business – i
- Syneron to Acquire TransPharma Medicalhttps://practicaldermatology.com/news/20120313-syneron_to_acquire_transpharma_medical/2459847/Syneron Medical Ltd. (NASDAQ: ELOS) has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd. TransPharma Medical, a specialty pharmaceutical company focused on the development and commercialization of drug-
- Tina Alster, MD Introduces LipoSonix to DC Areahttps://practicaldermatology.com/news/20120229-tina_alter_md_introduces_liposonix_to_dc_area/2459858/LipoSonix is now available at the Washington Institute of Dermatologic Laser Surgery for patients interested in reducing fat through body contouring. Tina Alster, MD provides treatments with The LipoSonix system, an FDA-cleared device that uses high inte
- ARTAS System Receives Canadian Medical Device License to Treat Hair Losshttps://practicaldermatology.com/news/20120229-artas_system_receives_canadian_medical_device_license_to_treat_hair_loss/2459861/Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS™ System has received a Canadian Medical Device License and can now be marketed and sold within Canada. The physician controlled ARTAS™ System allows them to quickly identify and harvest